Introduction {#s1}
============

Alemtuzumab, a humanized anti-CD52 monoclonal antibody (mAb), has consistently been shown to provide higher efficacy than the baseline disease-modifying agent interferon-beta1 and is approved in more than 65 countries for use in patients with active relapsing--remitting multiple sclerosis (RRMS) ([@B1]--[@B6]). Treatment with alemtuzumab leads to a depletion of circulating B- and T-lymphocytes, which is followed by reconstitution and rebalancing of the immune system, resulting in prolonged RRMS disease suppression. This process is characterized by differing alterations in numbers and proportions of different lymphocyte subsets ([@B7]--[@B9]). In contrast to the clear-out of conventional CD4^+^ T-cells (Tcon), an increase in frequencies of regulatory T-cells (Treg) early after initiating alemtuzumab therapy has been reported ([@B10]--[@B14]). This selective enrichment in Treg of the CD4^+^CD25^hi^CD127^low^FOXP3^+^ phenotype is of particular interest, as these cells are important regulators of the immune system ([@B15]). *In vitro*, Treg suppress Tcon immune responses in a dose-dependent manner ([@B16]), suggesting a potential impact of treatment-induced changes in the Treg/Tcon ratio. Alemtuzumab predominantly affects CD4^+^ T-cells exhibiting a CD45RO memory phenotype ([@B10]) and, thus, may also exert different differential effects on naïve and memory Treg subsets. Elucidating this aspect is important because Treg are functionally deficient in patients with MS, as we and others have previously shown ([@B17]--[@B22]). Of note, the loss of Treg suppressive properties is precipitated by contraction of CD45RA^+^ naïve and CD45RA^+^CD31^+^ recent thymic emigrant (RTE) subtypes and reciprocal expansion of memory phenotypes (CD45RO^+^) within peripheral Treg, a feature which possibly arises from premature immunosenescence ([@B23]--[@B25]). To decipher in detail the effects of alemtuzumab on the Treg compartment, we undertook a longitudinal study of 25 MS patients undergoing two cycles of treatment with alemtuzumab and assessed different parameters of Treg neogenesis and Treg suppressive function.

Methods {#s2}
=======

Human Samples
-------------

Our study included 25 patients with RRMS established according to the 2011 McDonald criteria ([@B26]), all of whom were scheduled for treatment with alemtuzumab, and 21 healthy donors. Alemtuzumab was administered as primary immunotherapy in 15 and as escalating treatment in 10 individuals, respectively. The mean disease duration was 6.3 years (range 2--13), the median age 32.3 years (17--53), and the median Expanded Disability Status Scale (EDDS) score 3.5 (1.0--6.5). During the observation period a total of nine relapses (year 1 post-treatment: *n* = 1, year 2 post-treatment: *n* = 8) occurred in eight patients, and one patient developed secondary autoimmune thyroiditis within 10 months after the second alemtuzumab administration. All patients were recruited in the Department of Neurology, University Hospital Heidelberg. Samples from 14/25 patients were repeatedly assessed over a period of 12 months after the second cycle of treatment. A total of 182 peripheral blood specimens (50--70 ml of EDTA blood and 10 ml of serum) were taken, directly before infusion and repeatedly thereafter (at day 7 and months 1, 3, 6, and 12 after each cycle). Plasma and serum samples were immediately stored at −70°C. The protocol was approved by the University Hospital Heidelberg ethics committee; all individuals gave written informed consent.

Cell Separation
---------------

Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-gradient centrifugation (Biochrom, Berlin, Germany). Total Treg and Tcon were highly enriched from freshly isolated PBMCs by means of immunomagnetic separation utilizing Dynabead technology as previously described ([@B19], [@B27], [@B28]).

Flow Cytometry
--------------

For quantitative and phenotypic characterization of Treg, Treg subsets, and Tcon subsets we used established multicolor flow cytometry protocols and gating strategies ([@B19], [@B24], [@B29], [@B30]). In short, freshly isolated PBMCs were immediately stained with a panel of mAbs specific for human Treg markers (anti-human CD4, CD45RO, CD45RA, CD31, CD127 \[BD Pharmingen\]; anti-human CD25 \[Miltenyi Biotech\]; anti-human FOXP3 \[eBioscience\]) ([Figure 1A](#F1){ref-type="fig"}), or alternatively for CD4, CD25, CD45RO, and CCR7 (**Figure 4A**), and then analyzed with a FACS Calibur™ cytometer using CellQuest™ software (BD Biosciences). To determine surface expression of CD52 on Treg and Tcon, PBMCs obtained from five healthy donors were co-stained with mAbs specific for Treg and Tcon and naive or memory phenotypes (see above) and a mAb specific for human CD52 (Alexa Fluor®488 conjugated, BD Biosciences). Mean fluorescence intensities (MFI) for CD52 were then determined in gated Tcon and Treg and in Tcon and Treg subtypes. Detection and quantification of Treg with two different T-cell receptor (TCR) Vα chains were achieved using a previously described protocol ([@B29], [@B31]). Briefly, fresh PBMCs were stained for Treg markers (see above) and with mAbs specific for human TCR-Vα2 (FITC-conjugated, Pierce) and Vα12 (APC-labeled with Zenon Mouse IgG Labeling Kit, Molecular Probes), identifying Vα2^+^, Vα12^+^ as well as Vα2^+^Vα12^+^ (double-positive) cells in gated Treg to calculate proportions of dual TCR cells as described ([@B29], [@B31]). To quantify alemtuzumab-induced cytolysis *in vitro*, Tcon or Treg tested in complement-dependent cytolysis assays were washed and then co-stained with mAbs specific for Treg and Tcon subtypes (see above) and propidium iodide (PI). Cytolysis rates for each subtype were calculated from the proportions of PI-positive cells after exposure to alemtuzumab minus the proportions of PI-positive cells after exposure to a control antibody.

![Treg repopulation is dominated by memory phenotypes. **(A)** Flow cytometry: Gating strategy for detection of Treg and Treg subtypes. Stained PBMCs were first gated on CD4 and CD127. CD4^+^CD127^low^ T cells were analyzed for co-expression of FOXP3 and CD25 identifying CD4^+^CD127^low^CD25^high^FOXP3^+^ Tregs. Tregs were then analyzed for expression of CD45RA and CD31 to identify CD45RA^+^ naive Tregs, CD45RA^−^ memory Tregs and CD45RA^+^CD31^+^ recent thymic emigrant (RTE)-Tregs. **(B)** Frequencies of Treg and Treg subsets in peripheral blood samples obtained from 25 RRMS patients before treatment (BT) and up to 24 months after two cycles of alemtuzumab. Each symbol represents an individual patient. Means are indicated by bold line. Statistical significances in differences of each time point compared to BT as determined by two-tailed non-parametric one-sample Wilcoxon sign rank test are indicated (n.s. = non-significant; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001; ^\*\*\*\*^*p* \< 0.0001).](fimmu-10-01204-g0001){#F1}

Cell Pro-Liferation Assay
-------------------------

To measure inhibitory capacities, patient- or donor-derived Treg were tested using *in vitro* proliferation assays against (a) syngeneic Tcon (obtained from the same patient) and (b) allogeneic Tcon (obtained from a frozen pool of Tcon from eight healthy donors). An amount of 4 × 10^4^ Tcon (either syngeneic or allogeneic) was incubated alone or in coculture with 1 × 10^4^ Treg (Treg/Teff ratio 1:4) and polyclonally activated by adding soluble anti-CD3 (1 μg/ml) and anti-CD28 mAbs (1 μg/ml). After 4 days, the cells were pulsed for 16 h with 1 μCi of ^3^\[H\]-thymidine per well. After harvesting, T-cell proliferation was measured with a scintillation counter.

Complement-Dependent Cytolysis Assay
------------------------------------

To screen for possible differences in alemtuzumab effects on Tcon and on Treg subsets, 2 × 10^5^ freshly isolated total Treg or Tcon obtained from five healthy subjects were incubated for 3 h at 37° with 10 μg/ml alemtuzumab (Genzyme) or control human IgG (Jackson ImmunoResearch) and 10% normal human complement (Quidel) in X-vivo 15 medium (BioWhittaker) supplemented with 10% FBS (Biochrom). After the incubation period, cells were washed and re-suspended in medium for subsequent flow cytometry analysis.

Quantification of T-Cell Receptor Excision Circles
--------------------------------------------------

Total DNA was extracted from freshly isolated Treg (1--3 × 10^5^ cells) using a QIAmp Blood Mini Kit (Qiagen) according to the manufacturer\'s protocol. Numbers of T-cell receptor-excision circles (TRECs) were determined by real time PCR as described elsewhere ([@B32]) and expressed as TRECs/10^6^ Treg.

CDR3 Spectratyping
------------------

First, total RNA was isolated from freshly isolated Treg (2--5 × 10^5^ cells) using a Rneasy Mini Kit (Qiagen) according to the manufacturer\'s protocol and then converted to cDNA using a SuperScript® III First-Strand Synthesis System (Invitrogen). For real-time PCR detection of all 24 TCR Vβ subfamilies ([@B33], [@B34]), 100 ng of cDNA was set in eight parallel PCR reactions, each containing three different Vβ specific primer sets and a 6-FAM-labeled C-primer for subsequent CDR3 spectratyping. Size distribution of 6-FAM-labeled PCR products was determined by laser-induced capillary electrophoresis with an automated DNA analyzer A310 and GeneScan software (Applied Biosystems). The complexity score within a Vβ subfamily was determined by counting the number of peaks per subfamily. Normal transcript size distribution consists of eight peaks for each V subfamily ([@B35]). A complexity score (CS) was calculated as the sum of scores of all 24 TCR Vβ subfamilies.

Statistical Analysis
--------------------

To determine whether differences in cell counts, inhibitory capacities, TREC levels, and TCR diversities were statistically significant, we performed non-parametric one-sample Wilcoxon sign rank tests using a two-tailed distribution with paired samples. No analysis of variance \[ANOVA\] was carried out, because data sets were not complete for all patients and all time points analyzed. A *p* value of ≤ 0.05 was considered to show be statistically significant difference in a descriptive sense. Two-sided *t*-tests and paired *t*-tests were used to compare normally distributed samples (cytolysis assay, CD52 expression). Again, a *p* value of ≤ 0.05 was considered to be statistically significant.

Results {#s3}
=======

Treg Recovery
-------------

Shortly after immune cell depletion by alemtuzumab (week 1) a concomitant reduction in numbers of circulating CD4^+^ T cells and Treg (2 ± 2/μl \[Treg cell count\]), was observable resulting in constant relative proportions of Treg (3.5 ± 2.4% \[of CD4^+^ T cells\]) among circulating CD4^+^ T-cells compared with baseline (19 ± 6/μl, 2.7 ± 1.5%; *p* = 0.008 and 0.285). In contrast, Treg numbers had recovered to 11 ± 5/μl at 1 months, translating into a massive increase in percentages among CD4^+^ T cells (18.1 ± 9.3%; *p* = 0.022 and \< 0.0001). Treg expansion then decreased, but proportions remained consistently higher at baseline throughout year 1 and year 2 ([Figure 1B](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}; [Figures S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}). At month 1, almost all Treg exhibited a CD45RO^+^ memory phenotype (Treg~memory~). The dominance of Treg~memory~ persisted throughout the study period, and CD45RO^+^ Treg accounted for ≥ 90% of CD4^+^ T-cells until month 12 of each treatment cycle ([Figure 1B](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). In contrast, frequencies of Treg with a naïve or RTE phenotype (Treg~naï*ve*~, Treg~RTE~) were barely detectable one month post-treatment and slowly recovered thereafter without returning to baseline levels. Whereas, total Treg at baseline comprised on average 23 and 12% Treg~naive~ and Treg~RTE~, Treg~naive~ accounted for 8% (*p* \< 0.001) and 7% (*p* \< 0.001) of T-cells and Treg~RTE~ for 6% (*p* \< 0.01) and 5% (*p* \< 0.01) of circulating CD4^+^ T-cells after 12 and 24 months, respectively ([Figure 1B](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Hence, these observations indicate that Treg are lysed together with other CD4^+^ T-cells and---in response to treatment-induced lymphopenia---then either expand to preferentially acquire a memory phenotype and/or are converted from post-depletional Tcon. Together with the decline in frequencies of Treg~RTE~, these changes---similar to what has been reported for CD4^+^ T-cells---do not favor replacement of Treg by thymic neogenesis.

###### 

Flow cytometry and PCR data obtained from 25 MS patients before and after two cycles of alemtuzumab.

                                                        **Treatment cycle 1**                    **Treatment cycle 2**                                                                                                                                                                                                                                         
  ------------------------ ---------------------------- ---------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------- --------------------------------------- ----------------------------------------- ------------------------------------------- -------------------------------------------
  Treg                     2.7 ± 1.5 (0.6--5.2)         3.5 ± 2.4 (0.9--8.4), *p* = 0.2849       18.1 ± 9.3 (8.0--39.6), *p* \< 0.0001     7.9 ± 3.4 (3.2--14.0), *p* \< 0.001       5.9 ± 2.8 (2.3--11.2), *p* \< 0.001         5.1 ± 1.9 (2.0--8.0), *p* \< 0.01       9.9 ± 3.5 (6.1--17.6), *p* \< 0.001       6.7 ± 1.6 (4.1--10.0), *p* \< 0.001         6.0 ± 1.2 (4.1--8.8), *p* \< 0.01
  Treg~naive~              22.5 ± 6.5 (11.5--36.9)      23.4 ± 5.1 (15.0--34.0), *p* = 0.7127    3.6 ± 3.3 (0.0--10.1), *p* \< 0.0001      5.1 ± 2.2 (0.5--10.9), *p* \< 0.0001      8.3 ± 2.3 (3.6--12.5), *p* \< 0.001         8.8 ± 2.3 (5.6--13.0), *p* \< 0.001     4.4 ± 2.2 (0.8--8.3), *p* \< 0.0001       6.2 ± 2.6 (2.7--11.5), *p* \< 0.001         7.0 ± 2.6 (2.9--12.2), *p* \< 0.001
  Treg~memory~             75.2 ± 7.1 (60.5--88.0)      71.3 ± 5.6 (60.0--79.9), *p* = 0.1174    95.5 ± 3.6 (88.1--100), *p* \< 0.0001     94.0 ± 2.4 (89.0--98.1), *p* \< 0.0001    92.0 ± 3.2 (85.5--99.3), *p* \< 0.001       89.0 ± 3.0 (82.1--92.4), *p* \< 0.001   94.7 ± 2.5 (90.3--99.8), *p* \< 0.001     91.7 ± 2.3 (87.7--95.4), *p* \< 0.001       89.9 ± 2.3 (86.5--94.2), *p* \< 0.01
  Treg~RTE~                12.2 ± 5.0 (6.0--23.9)       12.5 ± 5.3 (0.4--20.7), *p* = 0.9000     1.3 ± 1.3 (0.0--5.1), *p* \< 0.0001       4.6 ± 2.7 (1.1--10.0), *p* \< 0.001       6.4 ± 2.3 (2.3--11.6), *p* \< 0.01          7.1 ± 2.0 (5.1--10.8), *p* \< 0.01      2.4 ± 0.9 (0.9--4.7), *p* \< 0.001        4.3 ± 1.2 (1.9--6.5), *p* \< 0.001          5.4 ± 1.4 (3.0--7.8), *p* \< 0.01
  Dual-TCR-Treg            61.1 ± 4.5 (52.3--69.5)      58.9 ± 5.7 (48.0--66.0), *p* = 0.3550    45.6 ± 5.5 (37.4--53.9), *p* \< 0.001     47.9 ± 3.4 (41.0--53.7), *p* \< 0.001     49.9 ± 2.8 (45.1--54.0), *p* \< 0.001       50.2 ± 1.5 (44.5--55.2), *p* \< 0.001   46.0 ± 1.5 (41.0--52.7), *p* \< 0.001     49.2 ± 2.9 (42.9--53.6), *p* \< 0.001       51.0 ± 2.5 (47.0--55.6), *p* \< 0.01
  CDR3-complexity score    147 ± 7.1 (138--160)         n.a.                                     125 ± 7.6 (115--140), *p* \< 0.001        128 ± 5.8 (118--137), *p* \< 0.001        131 ± 5.6 (124--144), *p* \< 0.01           n.a.                                    127 ± 5.1 (121--138), *p* \< 0.01         129 ± 3.9 (124--136), *p* \< 0.01           133 ± 3.8 (129--141), *p* \< 0.05
  TRECs                    3.029 ± 846 (1,456--5,340)   n.a.                                     1.273 ± 448 (788--2,188), *p* \< 0.0001   1.397 ± 323 (980--2,104), *p* \< 0.0001   1.635 ± 359 (1,240--2,366), *p* \< 0.0001   n.a.                                    1.388 ± 431 (907--2,205), *p* \< 0.0001   1.494 ± 403 (1,054--2,243), *p* \< 0.0001   1.598 ± 370 (1,193--2,267), *p* \< 0.0001
  CCR7^−^CD45RO^+^ TEM     14.7 ± 5.4 (9.5--18.3)       54.3 ± 15.4 (44.2--61.7), *p* \< 0.001   n.a.                                      28.5 ± 12.3 (16.6--37.8), *p* \< 0.01     n.a.                                        n.a.                                    n.a.                                      n.a.                                        n.a.
  CCR7^−^CD45RO^−^ TEMRA   7.1 ± 5.1 (4.9--9.4)         17.6 ± 7.3 (12.1--22.8), *p* \< 0.001    n.a.                                      14.3 ± 7.3 (8.5--21.6), *p* \< 0.01       n.a.                                        n.a.                                    n.a.                                      n.a.                                        n.a.
  CCR7^+^CD45RO^+^ TCM     29.0 ± 10.4 (18.3--27.6)     12.5 ± 6.9 (9.4.2--19.3), *p* \< 0.001   n.a.                                      16.2 ± 6.8 (10.0--19.8), *p* \< 0.01      n.a.                                        n.a.                                    n.a.                                      n.a.                                        n.a.
  CCR7^+^CD45RO^−^ TCRA    38.9 ± 11.8 (31.0--46.2)     12.0 ± 4.6 (8.8.2--15.3), *p* \< 0.001   n.a.                                      19.4 ± 4.7 (13.9--22.6), *p* \< 0.01      n.a.                                        n.a.                                    n.a.                                      n.a.                                        n.a.

*Shown here are frequencies of Treg and CD4^+^ T cell subsets \[mean percentages ± standard deviation, minima and maxima (in parentheses), and statistical significance (before therapy vs. each time point thereafter). n.a. = not assessed*.

Treg Origin and Clonal Diversity
--------------------------------

The post-depletional Treg population contained invariably decreased proportions of dual-TCR cells and markedly contracted TREC numbers compared with Treg assessed at baseline, and the decline in these thymic-dependent markers persisted throughout months 1--12 after each alemtuzumab cycle ([Figures 2A,B](#F2){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Furthermore, as determined by CDR3 spectratyping post-treatment, Treg exhibited a reduced mean complexity score, reflecting a more pronouncedly constricted TCR repertoire than at baseline, a feature that lasted until month 12 of each treatment period ([Figure 2C](#F2){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Altogether, these findings are consistent with the notion that homeostatic proliferation of cells that have escaped depletion by alemtuzumab, rather than meaningful release of newly generated cells from the thymus, dominates the recovery phase in the Treg compartment.

![**(A)** Left side: Flow cytometry of stained PBMCs: After gating for Treg (see [Figure 1](#F1){ref-type="fig"}) Vα2^+^, Vα12^+^, and Vα2Vα12-double positive cells were identified and used to calculate the frequencies of %dual-TCR Treg. Right side: Proportions of dual-TCR Treg within the total Treg population of 25 RRMS patients before treatment (BT) and up to 24 months after two cycles of alemtuzumab. **(B)** TREC numbers per 10^6^ Treg within the total Treg population of 25 RRMS patients BT and up to 24 months after two cycles of alemtuzumab. **(C)** CDR3 spectratyping complexity score of total Treg cells. Each symbol represents an individual patient. Means are indicated by bold line. Statistical significances in differences of each time point compared to BT as determined by two-tailed non-parametric one-sample Wilcoxon sign rank test are indicated (n.s. = non-significant; ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).](fimmu-10-01204-g0002){#F2}

Treg Suppressive Function
-------------------------

When tested in cocultures with syngeneic effector T-cells, the suppressive function of post-depletional Treg remained constantly increased vs. baseline over the entire study period (before treatment (BT): 30.2 ± 5.6% \[mean percentage of Treg-mediated suppression of Tcon proliferation *in vitro*\]; year 1: 1 month: 45.6 ± 6.8%, *p* \< 0.001; 6 months: 45.1 ± 5.3%, *p* \< 0.001; 1 year: 40.9 ± 5.2%, *p* \< 0.01; year 2: 1 month: 43.7 ± 4.7%, *p* \< 0.001; 6 months: 43.8 ± 4.0%, *p* \< 0.001; 1 year: 42.3 ± 4.5%, *p* \< 0.001). Thus, the inhibitory function of post-depletional Treg nearly reached levels comparable to those seen in Treg obtained from healthy donors (51.1 ± 3.3%; [Figure 3A](#F3){ref-type="fig"}). In contrast, when co-cultured with allogeneic T-cells from normal donors, Treg inhibitory capacities remained more or less stable compared with their performance at baseline (BT: 29.9 ± 6.3%; year 1: 1 month: 33.5 ± 5.5%, *p* = 0.28; 6 months: 33.2 ± 5.5%, *p* = 0.33; 1 year: 30.8 ± 7.7%, *p* = 0.80; year 2: 1 month: 33.4 ± 5.6%, *p* = 0.29; 6 months: 32.2 ± 3.8%, *p* = 0.45; 1 year: 30.7 ± 6.0%, *p* = 0.82) and clearly reduced as compared to their counterparts from healthy control donors (50.2 ± 4.6%, *p* \< 0.001; [Figure 3B](#F3){ref-type="fig"}). Thus, repopulated Tcon obviously exhibited a decreased ability to resist regulation, thereby mitigating the MS-associated Treg defect previously described ([@B18]--[@B22]).

![Treg suppressive function. Inhibitory capacities of Treg isolated from peripheral blood samples obtained from six healthy donors (HC) and from 22 RRMS patients before treatment (BT) and up to 24 months after two cycles of alemtuzumab as tested by *in vitro* proliferation assays against **(A)** syngeneic Tconv (black diamonds) or **(B)** allogeneic Tconv (gray cubes). Means are indicated by bold line. Statistical significances in differences of each time point compared to BT as determined by two-tailed non-parametric one-sample Wilcoxon sign rank test are indicated (n.s. = non-significant; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).](fimmu-10-01204-g0003){#F3}

Repopulation of CCR7^+^ and CCR7^−^ Tcon
----------------------------------------

It was reported that treatment with alemtuzumab affects the balance between CD4^+^ T cells either expressing or lacking the C-C chemokine receptor type 7 (CCR7) ([@B11]). CCR7 is involved in homing of T cells to various secondary lymphoid organs including lymph nodes ([@B36]). We could previously demonstrate that in fingolimod-treated MS patients CCR7-negative Tcon expand and are more prone to Treg mediated suppression when tested in *in vitro* proliferation assays, thereby indirectly upregulating Treg efficiency ([@B30]). We therefore analyzed frequencies of circulating CCR7^+^ and CCR7^−^ CD4^+^ T-cell subsets before and post treatment with alemtuzumab in a subcohort of eight patients in the 1st year post-alemtuzumab by flow cytometry ([Figure 4A](#F4){ref-type="fig"}). At month 1, proportions of CCR7-expressing Tcon phenotypes (CCR7^+^CD45RO^+^ central memory cells, TCM; CCR7^+^CD45RO^−^ naive cells, TCRA) were massively decreased (BT: 67.9 ± 10.6% (mean percent of Tcon); 1 month 24.5 ± 6.1%, *p* \< 0.0001) and were still reduced at 6 and12 months (35.6 ± 5.9%, *p* \< 0.001). In contrast, the frequencies of CCR7^−^ Tcon subtypes (CCR7^−^CD45RO^+^ effector memory cells, TEM; CCR7^−^CD45RO^−^ cells, TEMRA) were expanded (BT: 21.8 ± 6.9%; 1 month: 71.9 ± 11.8%, *p* \< 0.0001; 6--12 months: 42.8 ± 8.5%, *p* \< 0.001) ([Figure 4B](#F4){ref-type="fig"}; [Table 1](#T1){ref-type="table"}).

![**(A)** Flow cytometry of stained PBMCs: After gating for Tcon cells were analyzed for surface expression of CCR7 identifying CCR7-expressing Tcon phenotypes (CCR7^+^CD45RO^+^ central memory cells, TCM; CCR7^+^CD45RO^−^ naive cells, TCRA) and CCR7^−^ Tcon subtypes (CCR7^−^CD45RO^+^ effector memory cells, TEM; CCR7^−^CD45RO^−^ cells, TEMRA). **(B)** Proportions of CCR7^+^ and CCR7^−^ subtypes within Tcon in peripheral blood samples obtained from eight RRMS patients before treatment (BT), and 1 month and 6--12 months after administration of alemtuzumab. Bars represent means with standard deviations. Statistical significances in differences of each time point compared to BT as determined by two-tailed non-parametric one-sample Wilcoxon sign rank test are indicated (^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001).](fimmu-10-01204-g0004){#F4}

CD52 Surface Expression and CD52-Mediated Cytolysis of Treg and Tcon
--------------------------------------------------------------------

Cellular CD52 expression on Treg, Tcon, and their subtypes was determined by flow cytometry of PBMCs obtained from five healthy donors. CD52 expression levels were higher on Tcon than on Treg (Tcon: MFI 1230 ± 203; Treg: 952 ± 188; *p* \< 0.05), and were significantly higher on naïve vs. memory subsets (Treg~naive~ 1,030 ± 192, Treg~memory~ 886 ± 174, *p* \< 0.05; Tcon~naive~ 1,281 ± 201, Tcon~memory~ 903 ± 177, *p* \< 0.01) ([Figure 5A](#F5){ref-type="fig"}).

![**(A)** Left side: Flow cytometry of stained PBMCs: After gating for Treg and Tcon, CD52 surface expressions were determined as mean fluorescence intensities (MFIs). Right side: CD52-MFIs of Treg, Tcon, and Treg and Tcon subsets obtained from peripheral blood samples of five HC. **(B)** CD52-mediated cytolysis of Treg, Tcon, and Treg and Tcon subsets isolated from peripheral blood samples of five HC as determined by a complement-dependent cytolysis assay *in vitro*. Bars represent means with standard deviations. Statistical significance as determined by Student\'s *t*-test is indicated (n.s. = non-significant; ^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01).](fimmu-10-01204-g0005){#F5}

To assess the effect of alemtuzumab on Treg and Tcon *in vitro*, freshly isolated Treg and Tcon obtained from five healthy donors were cultured alone for 3 h in the presence of 10 μg/ml alemtuzumab and 10% normal human complement. Cytolysis rates for each subtype were measured by flow cytometry as outlined in the methods section above, revealing that both Treg and Tcon were abundantly depleted in response to alemtuzumab (Treg: 88.2 ± 2.9% \[proportion of PI-positive cells\], Tcon: 86.7 ± 3.5%; *p* = 0.064; [Figure 5B](#F5){ref-type="fig"}). Moreover, cells with a naïve phenotype contained in both CD4^+^ populations were depleted more efficiently, although the difference did not attain statistical significance (Treg~naive~ 89.6 ± 4.2%, Treg~memory~ 87.8 ± 5.1%, *p* = 0.101; Tcon~naive~ 86.5 ± 3.6%, Tcon~memory~ 84.2 ± 4.0%, *p* = 0.071; [Figure 5B](#F5){ref-type="fig"}).

Discussion {#s4}
==========

Alemtuzumab-induced lymphocyte depletion is followed by an asymmetric repopulation of circulating T- and B-cells which also impacts Treg. Previous studies have shown that Treg rapidly increase relative to other CD4^+^ T-cell subsets and remain enriched up to several months after therapy ([@B10]--[@B14]). It is obvious that such numeric changes between Treg and Tcon or alterations affecting the homeostatic composition of subtypes comprised in both compartments are of high clinical relevance, as Treg are important mediators in the maintenance of peripheral immunotolerance by suppressing potentially autoaggressive Tcon clones. In patients with MS, a more detailed understanding of alemtuzumab-triggered depletion and recovery in the Treg population is of particular interest, since MS patient-derived Treg are less potent inhibitors of Tcon responses as a result of altered prevalence of naïve and mature Treg subtypes compared to healthy controls ([@B17]--[@B22]).

Here, we found that Treg are lysed together with other CD4^+^ T-cells, as reflected by equivalent relative proportions of CD4^+^CD25^high^CD127^low^FOXP3^+^ cells contained in total CD4^+^ T-cells at baseline and at 1 week after alemtuzumab administration. Accordingly, when exposed to alemtuzumab and human complement *ex vivo*, Treg were destroyed at least as efficiently as Tcon despite the somewhat lower membrane expression of CD52 on Treg. Again, the small difference in surface densities of CD52 featured by naïve vs. memory subsets translated into a slightly higher susceptibility of both Treg~naive~ and Tcon~naive~ to undergo complement-mediated cell lysis compared with the respective memory counterparts. Hence, Treg and Treg subsets are not spared from the effects of alemtuzumab.

The peak expansion of Treg at month 1 during post-treatment lymphocyte recovery featured a substantial dominance of Treg~memory~ over Treg~naï*ve*~ and thus mirrored the dynamics of reconstituting memory and naïve phenotypes in CD4^+^ and CD8^+^ T-cells described earlier ([@B10], [@B11]). The imbalance between Treg~memory~ and Treg~naï*ve*~ persisted until month 12 after both alemtuzumab cycles and was accompanied by a continued deficit in relative frequencies of Treg~RTE~. As numbers of TREC-containing and dual TCR-Treg---both markers intrinsic to thymocytes---remained low throughout the study period and coincided with a compromised TCR repertoire as documented by a reduced CDR3 complexity score, these observations altogether confirm that thymopoiesis is not or barely induced after alemtuzumab therapy, possibly due to the premature decline in thymic function attributed to MS ([@B19], [@B29], [@B30], [@B32]).

Whether the abundance of cells with a Treg phenotype among post-depletional total CD4^+^ T-cells, detectable from month 1 through month 12 independent of the underlying disease, as shown in our study and former studies, is driven by Treg formed extrathymically in the peripheral immune system by expansion of residual Treg and/or conversion from memory Tcon (induced or iTreg) during treatment-induced homeostatic proliferation ([@B10]--[@B14]) remains elusive, since currently, no features or phenotypic markers, including the Ikaros family transcription factor Helios, are able to distinguish iTreg from Treg generated by homeostatic proliferation ([@B37]). However, we observed in occasional patients (*n* = 2, data not shown) that Treg obtained shortly after treatment are not highly proliferative, as depicted by barely detectable intracellular expression of Ki-67, a nuclear antigen exclusively expressed during active cell cycling ([@B38]). As similar results were reported in a previous study, where only one out of four individuals assessed after treatment with Campath-1 showed a post-depletional slight increase in active cycling of Treg ([@B12]), these findings support the notion that homeostatic expansion does not solely account for the increased Treg/Tcon ratio.

A predominance of Treg~memory~ negatively affects the immunoregulatory properties of total Treg, as we and others have shown previously ([@B19], [@B23]--[@B25]). We therefore sought to establish how post-alemtuzumab Treg and Tcon interact to promote the restored long-term suppressive function of Treg observed in a former study ([@B11]). Of note, despite the more pronounced imbalance in Treg~naive~ and Treg~memory~ proportions inherent to post-treatment cells, the suppressive performance of total Treg appeared unexpectedly raised throughout months 1--24 when tested against Tcon isolated from the same patient. When employing allogeneic instead of syngeneic Tcon, however, Treg activity *per se* remained stable vs. baseline and decreased compared with counterparts from healthy donors. This, in turn, clearly indicates that post-alemtuzumab Treg remain dysfunctional, but perform better as an indirect result of a treatment-induced redistribution in Tcon phenotypes. Accordingly, the post-treatment Tcon population turned out to be enriched in CCR7^−^ TEM and TEMRA cells at the expense of CCR7^+^ naive TCM and TCRA subsets. The preponderance of such effector memory cells parallels our own observations in fingolimod-treated patients with MS, where Tcon lacking CCR7 become elevated during treatment and are less proliferative, thereby indirectly upregulating Treg efficiency ([@B30]). Importantly, it has been recently suggested, that protracted T-cell recovery and, hence, long-lasting lack of T-cell regulation along with earlier and even hyperproliferative B-cell subset reconstitution might serve as a main driver in the emergence of secondary autoimmunity in response to alemtuzumab therapy ([@B39]). Whether homeostatically disturbed Treg/Tcon subsets favor breakthrough MS activity remains elusive. In this study, the disease unequivocally remained clinically stable in the early post-treatment phase, i.e., when the ratio of absolute numbers of Tcon and Treg was lowest (month 1), whereas the Tcon/Treg ratio of recovering lymphocytes had reached at least around 50% of that measured at baseline in all nine relapses documented. However, the numeric relation between Tcon and Treg did not significantly differ in stable patients when assessed at the same points in time.

Conclusions {#s5}
===========

Taken together, Treg are not spared in alemtuzumab therapy and thymopoiesis does not considerably contribute to post-depletional long-term recovery. Reconstitution may be driven by homeostatic proliferation and/or by conversion from residual Tcon beginning after day 7 of treatment. This results in a relative Treg expansion among total CD4^+^ T-cells, which is, however, accompanied by a marked and long-lasting predominance of Treg~memory~ along with a contraction in Treg~naive~ and Treg~RTE~ as a response to therapeutic lymphopenia. As a result of these changes and the concomitant accumulation of effector memory populations in the Tcon compartment, the suppressive capacity of dysfunctional patient Treg is paradoxically restored. Importantly, intra-individual differences in repopulated Treg and Tcon may impact the therapeutic efficacy of alemtuzumab with respect to stabilization of MS activity. By showing that Treg undergo distinct and long-lasting homeostatic changes after alemtuzumab therapy, we challenge the beneficial influence deduced from the previously described apparent sparing of these cells from treatment-induced immune cell lysis ([@B10], [@B11], [@B13]).
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